Borderline resectable pancreatic cancer — what happens next

Someone has used the phrase borderline resectable pancreatic cancer about your scan, and the word doing all the damage is borderline. It sounds like a verdict left deliberately unfinished. It is not. Borderline is a defined category with a specific meaning and a well-worn route through it, and the first useful thing anyone can do for you is explain what it describes.

It describes a relationship between two things: your tumour, and the blood vessels that run immediately behind the pancreas. In a resectable tumour, there is clear space between the two. In a borderline tumour — what people search for as borderline pancreatic cancer, or an almost operable pancreas — the tumour is touching a vessel, or partly wrapped around one, closely enough that a surgeon could not be confident of removing it completely at that moment. In locally advanced disease the involvement is greater still. In metastatic disease the cancer has appeared somewhere beyond the pancreas, and the vessels are no longer the deciding question.

Two things follow from that, and both matter. Borderline is not a soft way of saying inoperable — it is a category with a defined plan attached. And the answer is not permanent. It is a description of where things stand on one scan, on one day, and it is expected to be asked again after treatment.

The vessels in question are the superior mesenteric and portal veins, which sit behind the neck of the pancreas, and the arteries nearby — the superior mesenteric artery, the coeliac axis and the common hepatic artery. Veins are more forgiving than arteries, because a segment of vein can be removed and rebuilt during an operation in a way that an artery usually cannot. Which vessel your report names, and how much of it is involved, changes the conversation completely; vascular involvement in pancreatic cancer sets out what each named vessel means in practice.

This judgement has to be made on the right scan. A pancreatic-protocol CT is a specific study — thin slices, timed contrast phases — not the same as a routine abdominal scan that happened to find something. A tumour called borderline on an ordinary scan is worth re-reading properly before anyone builds a plan on it. If you want the wider map of the disease before the detail on this page, start with our complete guide to pancreatic cancer.

One thing to be plain about early. CION does not perform pancreatic surgery in-house. The operation, including any vein resection, is coordinated with specialist hepatobiliary and gastrointestinal surgical partners, carried out at their hospital, and that part of your care may be billed there. What CION runs directly, across 35+ centres, is everything that surrounds the surgical question: the staging scans and their reporting, the tumour-board decision on which category you are in, the chemotherapy that comes first, radiation where it is indicated, nutrition and enzyme support, pain and psycho-oncology, and the long follow-up afterwards.

1. 1

   The scan is re-read against the written criteria

   Your pancreatic-protocol CT, and an MRI or MRCP where it adds something, is read specifically for the tumour’s relationship to each named vessel — not simply for whether a mass is present. Where the study was not a pancreatic protocol, it is repeated properly first.

   In-house at CION
2. 2

   Tissue is obtained before treatment begins

   Because treatment starts before any operation, a biopsy is needed to confirm what the tumour is. This is usually taken through an endoscopic ultrasound. It is arranged and scheduled by us and performed at a partner endoscopy unit.

   Coordinated with endoscopy partners
3. 3

   Jaundice is relieved, if it is present

   A tumour in the head of the pancreas often blocks the bile duct. Where jaundice is deep, the duct is drained with a stent placed at ERCP before chemotherapy can safely start. That procedure sits with our gastroenterology partners and may be billed there.

   Coordinated with endoscopy partners
4. 4

   Systemic treatment comes first

   Combination chemotherapy is given before any operation. It treats disease too small for a scan to show, and it reveals how the tumour behaves before you are committed to major surgery — chemotherapy before surgery and downstaging covers this phase in full.

   In-house at CION
5. 5

   Radiation, in selected cases

   After chemotherapy, radiation or chemoradiation is sometimes added where the concern is a specific margin close to a vessel. It is a considered addition to the plan rather than a routine one, and it is planned and delivered by our radiation oncology team.

   In-house at CION
6. 6

   You are restaged, and the question is asked again

   A repeat scan, the trend in CA 19-9 where it was raised, your weight and your stamina are looked at together. The scan alone is a poor guide here, because pancreatic tumours often respond without visibly shrinking, so no single measure decides this.

   In-house at CION
7. 7

   A fresh decision, made at tumour board

   Medical, surgical and radiation oncologists review the new picture together. Where there is doubt about disease too small to image, a short camera look inside — a staging laparoscopy — is arranged with our surgical partners before a major operation is committed to.

   CION board; laparoscopy coordinated
8. 8

   Surgery, or a continued systemic plan

   If the operation goes ahead it is performed by partner hepatobiliary surgeons, sometimes removing and rebuilding a segment of vein. If it does not, treatment continues rather than stops — see pancreatic cancer treatment in Hyderabad for what that looks like.

   Surgery coordinated; oncology in-house

• Which vessel exactly, and how much of it is involved? Ask for the vessel to be named. “It is near a blood vessel” is not enough to plan around.
• Vein or artery? The distinction changes what surgery can offer — vascular involvement explained sets out why.
• Was this judged on a pancreatic-protocol CT? If the finding came from a routine abdominal scan, the category is worth confirming on a proper study first.
• Who decided the category — one doctor, or a tumour board? NCCN guidance expects multidisciplinary review before treatment begins, not after it.
• When will I be restaged, and on what will the decision rest? Ask what will be weighed alongside the scan, because tumour shrinkage is a weak measure on its own.
• If the operation becomes possible, would it involve vein resection? Surgery with vascular resection is a bigger operation and belongs in experienced hands.
• Where would the operation happen, and who bills for which part? Ask for the split between the surgical hospital and your oncology team in writing.
• What is the plan if the tumour does not move off the vessel? A good answer exists, and hearing it now makes the waiting far easier.

A borderline diagnosis puts you in a waiting period that has a purpose. Treatment is happening the whole time, and the surgical question is being re-asked at a planned point rather than left hanging. Holding that plan steadily is the work, and it starts with a free 45-minute consultation — long enough to read your scans with you, say which category you are in and why, and set out what happens in what order.

Through the systemic phase, the practical job is keeping you well enough to remain a surgical candidate. Weight, muscle, blood sugar and jaundice all matter here, and they are the things most often left unattended while everyone watches the tumour. Pancreatic enzyme replacement, dietetic input, control of pain and attention to type 3c diabetes are delivered in-house, and they are not side issues — a person who has lost significant weight and strength may be turned down for an operation that their tumour would otherwise have allowed.

At restaging, the honest position is worth stating plainly. Chemotherapy first can move a tumour off a vessel and make an operation possible that was not possible on the first scan, and that is one of the genuinely hopeful facts in pancreatic cancer. It does not always happen. There is no guarantee that a borderline tumour becomes operable, and anyone who promises you one is not being straight with you. What we will do is tell you where you stand at each review, in words you can repeat to your family.

If the answer at restaging is that surgery is still not the right operation, that is not the end of treatment and it is not a failure of the plan. Systemic therapy continues, radiation may be added, symptoms are treated actively, and the question can be asked a third time if the picture changes again. If the answer is that surgery is now reasonable, the case goes to a partner hepatobiliary team with the whole record behind it — and where the vein is involved, to a unit that does resection with vascular reconstruction regularly.

One commitment worth stating. No rushed decisions, and no unnecessary tests. If an operation is not realistic for you, we will say so and explain exactly why, rather than leaving you to work it out from what nobody said.

1. 1

   Your scans are read in front of you

   Bring the discs, not only the reports. We look at the tumour against each named vessel, because that relationship is the whole of the borderline question.

   In-house at CION
2. 2

   The category is said plainly

   Resectable, borderline resectable, locally advanced or metastatic — along with what would have to change for that answer to change, and roughly when it will be asked again.

   In-house at CION
3. 3

   Tumour board, not one opinion

   Your case is reviewed by medical, surgical and radiation oncologists together, and the partner surgeon’s view forms part of that discussion before any date is offered.

   In-house at CION
4. 4

   The sequence is written down for you

   What happens first, what follows it, when the restaging scan falls, and which parts happen at a partner hospital. You leave with the order of events, not a vague reassurance.

   In-house at CION
5. 5

   Costs and cover, before you commit

   A written estimate, an explicit split between what CION bills and what the partner hospital bills, and whether Aarogyasri, NTR Vaidya Seva or your own insurance applies to each part.

   In-house at CION

Medical disclaimer: This page explains what the borderline resectable category means in pancreatic cancer and how the pathway around it is organised, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma. It is general information and not an individual surgical or oncological opinion; your own category, treatment sequence and suitability for an operation depend on your imaging, pathology and fitness and must be decided with your treating team. Pancreatic-protocol CT and MRI/MRCP ordering and reporting, CA 19-9 and bloods, tumour-board resectability assessment, chemotherapy, radiation, chemoradiation and SBRT, genetic counselling, nutrition and pancreatic enzyme (PERT) support, pain, psycho-oncology and survivorship care are delivered by CION. All pancreatic surgery including resection with vascular reconstruction, staging laparoscopy, endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.